Evidence map›Paper›PMID 38755194›Full record

ReviewNature reviews. Disease primers2024

Paediatric hydrocephalus.

Kristopher T Kahle, Petra M Klinge, Jenna E Koschnitzky, Abhaya V Kulkarni, Nanna MacAulay, Shenandoah Robinson, Steven J Schiff, Jennifer M Strahle

Registry-linked trialAbstract readReview
In one paragraph

Review in Nature reviews. Disease primers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07662174 (VENTURE-PHH), which is not on this map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07662174 phase1 / phase2not yet recruitingnot on this mapstarted 2027, after this paper: background citation

VENTURE-PHH: Ventricular mTOR Inhibition to Prevent Hydrocephalus After Brain Hemorrhage

TypeinterventionalSponsorMassachusetts General HospitalRan2027 to 2027Enrolled15ConditionsPost-hemorrhagic Hydrocephalus (PHH)ArmsSirolimus (Rapamune®)
3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Repurposing Cell Cycle Oscillators for Multiciliated Cell Differentiation.Advances in experimental medicine and biology · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Factors affecting infection risk and revision rates in shunted pediatric hydrocephalus: 10 years of data from a single academic center.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kristopher T KahleDepartment of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. kahle.kristopher@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-5922-7547
Petra M KlingeDepartment of Neurosurgery, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, USA.
Jenna E KoschnitzkyDepartment of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Abhaya V KulkarniDivision of Paediatric Neurosurgery, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Nanna MacAulayDepartment of Neuroscience, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-7800-6600
Shenandoah RobinsonDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Steven J SchiffDepartment of Neurosurgery, Yale University, New Haven, CT, USA.
Jennifer M StrahleDepartment of Neurosurgery, Washington University School of Medicine, Saint Louis, MO, USA.

Funding

Endoscopic versus Shunt Treatment of Hydrocephalus in InfantsU01NS107486 · NINDS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Richard Holubkov, John Kestle · 2019 to 2026
$9.6M
Predictive Personalized Public Health (P3H): A Novel Paradigm to Treat Infectious DiseaseR01AI145057 · NIAID · YALE UNIVERSITY · PI SCHIFF, STEVEN J · 2018 to 2022
$8.1M
Neurocognitive outcomes and changes in brain and CSF volume after treatment of post-infectious hydrocephalus in Ugandan infants by shunting or ETV/CPC: a randomized prospective trialR01HD085853 · NICHD · YALE UNIVERSITY · PI KULKARNI, ABHAYA V, SCHIFF, STEVEN JOHN · 2015 to 2025
$4.7M
Safety of Combinatorial Therapy with Erythropoietin and Melatonin for Preterm Infants with Intraventricular HemorrhageR01HD104673 · NICHD · JOHNS HOPKINS UNIVERSITY · PI SHENANDOAH ROBINSON · 2022 to 2026
$2.6M
Human Genetics and Molecular Mechanisms of Congenital HydrocephalusR01NS111029 · NINDS · YALE UNIVERSITY · PI DENIZ, ENGIN, JIN, SHENG CHIH · 2020 to 2024
$2.5M
Ependymal Dysfunction in Neonatal Post-Hemorrhagic HydrocephalusR01NS110793 · NINDS · WASHINGTON UNIVERSITY · PI STRAHLE, JENNIFER · 2019 to 2023
$2.5M
Modulation of Choroid Plexus Immuno-secretory Function to Restore Cerebrospinal Fluid Homeostasis in HydrocephalusR01NS109358 · NINDS · YALE UNIVERSITY · PI Kristopher T. Kahle · 2018 to 2026
$2.4M
NIAID NIH HHS R01 AI145057NICHD NIH HHS R01 HD085853NICHD NIH HHS R01 HD104673NINDS NIH HHS R01 NS109358NINDS NIH HHS R01 NS110793NINDS NIH HHS R01 NS111029NINDS NIH HHS U01 NS107486
6 · The paper itself

Abstract

Hydrocephalus is classically considered as a failure of cerebrospinal fluid (CSF) homeostasis that results in the active expansion of the cerebral ventricles. Infants with hydrocephalus can present with progressive increases in head circumference whereas older children often present with signs and symptoms of elevated intracranial pressure. Congenital hydrocephalus is present at or near birth and some cases have been linked to gene mutations that disrupt brain morphogenesis and alter the biomechanics of the CSF-brain interface. Acquired hydrocephalus can develop at any time after birth, is often caused by central nervous system infection or haemorrhage and has been associated with blockage of CSF pathways and inflammation-dependent dysregulation of CSF secretion and clearance. Treatments for hydrocephalus mainly include surgical CSF shunting or endoscopic third ventriculostomy with or without choroid plexus cauterization. In utero treatment of fetal hydrocephalus is possible via surgical closure of associated neural tube defects. Long-term outcomes for children with hydrocephalus vary widely and depend on intrinsic (genetic) and extrinsic factors. Advances in genomics, brain imaging and other technologies are beginning to refine the definition of hydrocephalus, increase precision of prognostication and identify nonsurgical treatment strategies.

Indexed as

HydrocephalusCerebrospinal Fluid ShuntsChildHumansInfantInfant, NewbornVentriculostomy

Identifiers

PMID38755194
PMCPMC12091269

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.